Proleukin aldesleukin
Drug Class
Recombinant human interleukin-2重组人白细胞介素-2
Mechanism
Acts as an immunological modifier that stimulates T-cell and natural killer (NK) cell activation and proliferation, promoting host immune defense against tumor cells.作为一种免疫调节分子，能够刺激T细胞和天然杀伤（NK）细胞的活化与增殖，激活机体自身的免疫防线以攻击并杀伤肿瘤细胞。
Approved Indication
Metastatic renal cell carcinoma and metastatic melanoma, per its FDA approval.根据美国FDA批准，适用于转移性肾细胞癌以及转移性黑色素瘤的治疗。
What This Means For Patients
Proleukin is an immunotherapy drug that uses high-dose recombinant interleukin-2 to stimulate the patient's own immune system to fight metastatic kidney cancer or melanoma. It is available under the special import policy in Hainan Boao Lecheng.Proleukin是一种应用高剂量重组人白细胞介素-2的免疫疗法，旨在激活患者自身的免疫系统以对抗转移性肾癌或黑色素瘤。可通过海南博鳌乐城的特许政策进口引进。
Regulatory Approvals
- FDA — approved (1992) — source
Pivotal Clinical Evidence
- Aldesleukin RCC Study Group — Fyfe et al., J Clin Oncol 1995 — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.